Denali Therapeutics DNLI 深 沪
交易中 10-06 10:35:07 美东时间
19.10
-0.810
-4.07%
华盛通- 最 高25.2683
- 今 开19.93
- 成交量 14.53万股
- 最 低 19.10
- 昨 收 19.91
- 总市值 234.93万
- 52周最高 27.30
- 市盈率 静 --
- 换手率 118.13%
- 52周最低 13.75
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 93.94
- 量 比 0.62
- 振 幅 30.98%
- 历史最低 1.10
- 每 手 1
- 风险率 2.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2 data readout by late 2026.
04-07 01:26
FDA Approves Denali Therapeutics' Avlayah To Treat Hunter Syndrome
https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome
03-25 23:48
FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment
REGENXBIO shares fall after the FDA issues a response letter on its Hunter syndrome gene therapy, raising trial design concerns and pushing the approval timeline.
02-10 21:51
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.
2025-12-06 00:49
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. deposited $874.78 into its trust account to extend its business combination deadline to July 11, 2025. The funds were provided through a $180,000 convertible promissory note from Scilex Holding Company, with no interest, repayable upon business combination or liquidation. The note is convertible into Class A shares at $10 per share. Remaining funds may extend the deadline further.
2025-06-12 00:30
Cantor Fitzgerald Reiterates Overweight on Denali Therapeutics, Maintains $35 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and maintains $35 price target.
2024-09-09 23:36
B of A Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $29
B of A Securities analyst Tazeen Ahmad maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $29.
2024-09-04 19:37
Wedbush Adjusts Price Target on Denali Therapeutics to $27 From $26, Maintains Outperform Rating
06:15 AM EDT, 09/04/2024 (MT Newswires) -- Denali Therapeutics (DNLI) has an average buy rating and a price target range of $22 to $90, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia ...
2024-09-04 18:15
